Sponsor Deadline
Posted: 12/7/2023

Clinical Trial Awards (CTA) Program

There is an urgent need for new and improved therapies for ALS, as there is still no cure. Clinical trials are the most reliable – and ultimately the fastest – way to translate promising laboratory science into new and better ways to treat and care for people living with ALS. The ALS Association’s Clinical Trial Awards seek to de-risk clinical programs of novel or repositioned approaches for ALS by providing up to $1,000,000 in total funding over 2 or 3 years to support early- to mid-stage trials (phase 1 or phase 2a). These awards are open to industry and academic investigators, and both disease-modifying and symptomatic treatments are in scope.  

Successful applicants will provide strong preclinical data supporting the biological rationale for the proposed treatment and a clear plan for clinical development. Biomarker-driven clinical trials, along with other methods for increasing the probability that trials definitively answer relevant scientific questions, are strongly encouraged. Long-term development plans should describe essential “go/no-go” decision milestones and a plan to attract follow-on funding if results are positive. 

Letter of Intent Due: Jan. 25, 2024

Eligibility Requirements

This program is open to both industry and academic investigators. Individuals with the skills, knowledge, and resources necessary to carry out the proposed research may apply as a principal investigator. Postdoctoral fellows are not eligible to apply as principal investigators.

Amount Description

Budgets for total costs up to $1,000,000 (inclusive of both direct and indirect costs) may be requested for a period of 2 or 3 years. Indirect costs are limited to 10% of total direct costs.  

Funding Type